DPP-4 Inhibitors
ApprovedSmall molecule
Boehringer IngelheimDPP-4 Inhibitors is one of 146 small molecule programs targeting Acute Pancreatitis. It is currently in Approved.
6
Indications
11
Total Trials
1
Active Trials
145
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1063 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1DPP-4 Inhibitors
Boehringer IngelheimApproved
Gemzar
GGynecologic Oncology Group
Preclinical
MS Contin
Merck & Co.Preclinical
Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
ABI-007
Bristol-Myers SquibbPreclinical
Active Comparator
ModernaPreclinical
LDE225
NovartisPreclinical
Sulfonylureas
Eli LillyPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Type 2 Diabetes3 trials
Pancreatic Cancer1 trial
Incretin-based Drugs and Pancreatic Cancer
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02475499·886,172 enrolled
Diabetic Ketoacidosis1 trial
Acute Pancreatitis1 trial
Incretin-based Drugs and Acute Pancreatitis
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02476760·1,417,914 enrolled
4 more indications
Type 2 Diabetes Mellitus1 trial
The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria
Active, not recruiting·—·N/A·NCT06611904·60 enrolled
Heart Failure1 trial
Incretin-based Drugs and the Risk of Heart Failure
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02456428·1,499,650 enrolled
Alzheimer disease1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DPP-4 Inhibitors. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company